Evolus logo
EOLSEvolus
Trade EOLS now
Evolus primary media

About Evolus

Evolus (NASDAQ:EOLS) is a performance beauty company with a focus on medical aesthetics. The company's flagship product, Jeuveau®, aims to enhance the aesthetic appearance of consumers by reducing the appearance of facial lines and wrinkles. Evolus is committed to innovation in the rapidly growing aesthetics market, seeking to deliver advanced products that meet the evolving needs of its customers. With a customer-centric approach, the company is dedicated to providing top-tier service and support to its practitioners and their clients, ensuring a positive experience with their treatments. Evolus's objective is to be at the forefront of the beauty industry by expanding its product offerings and presence in the global market, emphasizing safety, quality, and customer satisfaction.

What is EOLS known for?

Snapshot

Public US
Ownership
2012
Year founded
296
Employees
Newport Beach, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Newport Beach, US

Products and/or services of Evolus

  • Jeuveau, a proprietary formulation of prabotulinumtoxinA-xvfs for temporary improvement of moderate to severe frown lines.
  • Customer loyalty programs aimed to enhance patient retention and satisfaction for Jeuveau treatments.
  • Strategic partnership initiatives for market expansion and distribution of Jeuveau in international territories.
  • Investment in research and development to improve existing formulations and explore new applications for botulinum toxin products.
  • Digital marketing campaigns and educational programs to increase brand awareness and product knowledge among healthcare professionals.
  • Development and implementation of a state-of-the-art customer service platform to streamline the ordering process and support for medical practitioners.

Evolus executive team

  • Mr. David MoatazediPresident, CEO & Director
  • Ms. Tomoko Yamagishi-DresslerChief Marketing Officer
  • Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.Chief Medical Officer and Head of Research & Development
  • Ms. Tatjana MitchellChief Financial Officer
  • Mr. Nareg SagherianHead of Global Investor Relations & Corporate Communications
  • Mr. Jeffrey J. PlumerGeneral Counsel
  • Mr. Kurt KnabSenior Vice President of Sales
  • Ms. Jessica NovakSenior Vice President of Human Resources

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.